Price history
¥4,515Latest+55.5%
Drag across the chart to measure the move between two points.Delayed 15 minutes · monthly closing basis
Business overview
A summary lands here once the filings have been read.
Recurring subjects
No threads yetThis company's filings have not been read yet. We are adding them progressively.
Companies sharing a theme
News
Key numbersShowing 8 of 17
PER
7.77How many years of earnings it would take to buy the stock. The market average is generally considered to be around 15.PBR
0.47How many times the company's net assets? Around 1x is generally considered a benchmark.ROE
6.1%Earning power. A figure above 10% is generally considered good.Equity ratio
44.6%The proportion of assets funded by money that does not have to be repaid.Operating margin
2.5%The percentage of revenue remaining from the company’s core business.Revenue growth (3 years)
0.6%The average annual growth in sales over the past three years.Forward P/E
8.2Forward P/E based on estimated earnings for the next fiscal year.PSR
0.15The number of times sales are valued. Used to assess companies that are not profitable.What to watch next
Evidence of improved operating efficiency, inventory management, and shipping-error controls following the core-system investment, including completion and stabilization of operations
2026 onward (the data provides limited explicit information on the completion of recent investments)Impact MediumLikelihood Medium
The integration benefits of the 2023 absorption-type merger of 東北システム, including improved sales and administrative efficiency and a better cost structure
2026 onward (the effects of the integration require validation through earnings disclosures)Impact MediumLikelihood Medium
The point at which progress toward eliminating inefficiencies and variability and expanding gross margins becomes visible, through year-end results or updates on medium-term plan progress
When the medium-term plan is updated, either annually or during the fiscal yearImpact HighLikelihood Medium
The impact of revisions to the National Health Insurance drug price standard, including the potential reduction in sales price ceilings and the resulting effect on pharmaceutical-related sales and gross profit
Revision periods, linked to the annual regular schedule, although the data provides less explicit information on the latest yearImpact HighLikelihood Medium
Whether cost and demand fluctuations caused by geopolitical and macroeconomic uncertainty, including Russia and Ukraine, continue, and whether the assumption that the impact will be limited is updated
Quarterly, when risk disclosures are updatedImpact MediumLikelihood Medium
What to watch next
Who owns itTop holders total 48.9%
Listed holders 48.9%Everyone else 51.1%
Aomori Michinoku Bank, Ltd.9.90%
東北化学薬品取引先持株会9.10%
東北化学薬品従業員持株会5.80%
Tokyo Small and Medium Enterprise Investment & Consultation Co., Ltd.5.60%
Azuma Yasuo (東 康夫)4.60%
Azuma Yasuyuki (東 康之)3.60%
東ソー・ニッケミ株式会社3.40%
Nippon Soda Co.,Ltd.2.40%
2 other listed holders4.50%
| Holder | Ownership (%) |
|---|---|
| Aomori Michinoku Bank, Ltd. | 9.90 |
| 東北化学薬品取引先持株会 | 9.10 |
| 東北化学薬品従業員持株会 | 5.80 |
| Tokyo Small and Medium Enterprise Investment & Consultation Co., Ltd. | 5.60 |
| Azuma Yasuo (東 康夫) | 4.60 |
| Azuma Yasuyuki (東 康之) | 3.60 |
| 東ソー・ニッケミ株式会社 | 3.40 |
| Nippon Soda Co.,Ltd. | 2.40 |
| 2 other listed holders | 4.50 |
This company's documents
Filings
Timely disclosures
- 2026-07-31Notice Regarding Revisions to Full-Year Earnings Forecast
- 2026-07-31Financial Results for the Third Quarter of the Fiscal Year Ending September 2026 [Japanese GAAP] (Consolidated)
- 2026-05-01Notice Regarding Differences Between Forecast and Actual Results
- 2026-05-01Summary of Financial Results for the Second Quarter (Interim Period) of the Fiscal Year Ending September 2026 [Japanese GAAP] (Consolidated)